Molecular biology of bladder cancer: Prognostic, and clinical implications

Clinical Genitourinary Cancer

Volumn 5, Issue 1, 2006, Pages 67-77

  Mirra, Anirban P ^a   Lin, Henry ^a   Datar, Ram H ^a   Cote, Richard J ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Angiogenesis; Apoptosis; Cell cycle; Expression profiling; Molecular pathways; Multiple marker analysis; Prognostic markers; Urothelial carcinoma

Indexed keywords

ACIDIC FIBROBLAST GROWTH FACTOR; BASIC FIBROBLAST GROWTH FACTOR; CISPLATIN; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN E; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GELATINASE A; GELATINASE B; HYPOXIA INDUCIBLE FACTOR 1; METHOTREXATE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATELET DERIVED GROWTH FACTOR; PROTEIN BAX; PROTEIN BCL 2; PROTEIN MDM2; PROTEIN P16; PROTEIN P21; PROTEIN P27; PROTEIN P53; RETINOBLASTOMA PROTEIN; SCATTER FACTOR; THROMBOSPONDIN 1; UROKINASE; VASCULOTROPIN; VINBLASTINE; APOPTOSIS REGULATORY PROTEIN; CELL CYCLE PROTEIN;

ADJUVANT THERAPY; ANGIOGENESIS; APOPTOSIS; ARTICLE; BLADDER CANCER; BLADDER CARCINOGENESIS; CANCER STAGING; CELL CYCLE; CELL CYCLE PROGRESSION; CHROMOSOME 9; CYSTECTOMY; DISEASE COURSE; DRUG TARGETING; ENZYME IMMUNOASSAY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE IDENTIFICATION; GENETIC ANALYSIS; GENETIC TRANSCRIPTION; HETEROZYGOSITY LOSS; HUMAN; IMMUNOHISTOCHEMISTRY; INDIVIDUALIZATION; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MEDICAL DECISION MAKING; MICROARRAY ANALYSIS; MOLECULAR BIOLOGY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT CARE; PREDICTION; PROGNOSIS; RECURRENCE RISK; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; WESTERN BLOTTING; ZYMOGRAPHY; BLADDER TUMOR; GENETIC MARKER; GENETICS; NEOVASCULARIZATION (PATHOLOGY); PHYSIOLOGY; REVIEW; TUMOR SUPPRESSOR GENE;

APOPTOSIS REGULATORY PROTEINS; CELL CYCLE PROTEINS; GENES, P53; GENETIC MARKERS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; URINARY BLADDER NEOPLASMS;

EID: 33749053635     PISSN: 15587673     EISSN: None     Source Type: Journal    
DOI: 10.3816/CGC.2006.n.020     Document Type: Article

References (139)

1. Cote RJ, Soni RA, Amin MB. Bladder and urethra. In: Weidner N, Cote RJ, Suster S, et al, eds. Modern Surgical Pathology. Philadelphia, PA: WB Saunders Co; 2003:1102-1147.
2. International Agency for Research on Cancer. GLOBOCAN 2000: Cancer incidence, mortality and prevalence worldwide. IARC Cancerbase No.5 version 1.0. Lyon: IARC Press; 2001. Available at: URL: http://www-dep.iarc.fr. Accessed February 26, 2006.
3. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006; 56-106-130.
4. Trosko JE, Chang CC. Role of tumor promotion in affecting the multi-hit nature of carcinogenesis. Basic Life Sci 1985; 33:261-284.
5. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57-70.
6. Esrig D, Elmajian D, Groshen S, et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 1994; 331:1259-1264.
7. Stein JP, Ginsberg DA, Grossfeld GD, et al. Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer. J Natl Cancer Inst 1998; 90:1072-1079.
8. Cote RJ, Dunn MD, Chatterjee SJ, et al. Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Res 1998; 58:1090-1094.
9. Takagi Y, Takashi M, Koshikawa T, et al. Immunohistochemical demonstration of cyclin D1 in bladder cancers as an inverse indicator of invasiveness but not an independent prognostic factor. Int J Urol 2000; 7:366-372.
10. Simon R, Struckmann K, Schraml P, et al. Amplification pattern of 12q13-q15 genes (MDM2, CDK4, GLI) in urinary bladder cancer. Oncogene 2002; 21:2476-2483.
11. Makiyama K, Masuda M, Takano Y, et al. Cyclin E overexpression in transitional cell carcinoma of the bladder. Cancer Lett 2000; 151:193-198.
12. Sgambato A, Migaldi M, Faraglia B, et al. Loss of P27Kip1 expression correlates with tumor grade and with reduced disease-free survival in primary superficial bladder cancers. Cancer Res 1999; 59:3245-3250.
13. Orlow I, LaRue H, Osman I, et al. Deletions of the INK4A gene in superficial bladder tumors. Association with recurrence. Am J Pathol 1999; 155:105-113.
14. Hussain SA, Ganesan R, Hiller L, et al. BCL2 expression predicts survival in patients receiving synchronous chemoradiotherapy in advanced transitional cell carcinoma of the bladder. Oncol Rep 2003; 10:571-576.
15. Hussain SA, Ganesan R, Hiller L, et al. Proapoptotic genes BAX and CD40L are predictors of survival in transitional cell carcinoma of the bladder. Br J Cancer 2003; 88:586-592.
16. Bochner BH, Esrig D, Groshen S, et al. Relationship of tumor angiogenesis and nuclear p53 accumulation in invasive bladder cancer. Clin Cancer Res 1997; 3:1615-1622.
17. Grossfeld GD, Ginsberg DA, Stein JP, et al. Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression. J Natl Cancer Inst 1997; 89:219-227.
18. Jones A, Fujiyama C, Blanche C, et al. Relation of vascular endothelial growth factor production to expression and regulation of hypoxia-inducible factor-1 alpha and hypoxia-inducible factor-2 alpha in human bladder tumors and cell lines. Clin Cancer Res 2001; 7:1263-1272.
19. O'Brien T, Cranston D, Fuggle S, et al. Different angiogenic pathways characterize superficial and invasive bladder cancer. Cancer Res 1995; 55:510-513.
20. Mizutani Y, Okada Y, Yoshida O. Expression of platelet-derived endothelial cell growth factor in bladder carcinoma. Cancer 1997; 79:1190-1194.
21. Lipponen P, Eskelinen M. Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis. Br J Cancer 1994; 69:1120-1125.
22. Papathoma AS, Petraki C, Grigorakis A, et al. Prognostic significance of matrix metalloproteinases 2 and 9 in bladder cancer. Anticancer Res 2000; 20:2009-2013.
23. Hasui Y, Marutsuka K, Asada Y, et al. Prognostic value of urokinase-type plasminogen activator in patients with superficial bladder cancer. Urology 1996; 47:34-37.
24. Gazzaniga P, Gandini O, Gradilone A, et al. Detection of basic fibroblast growth factor mRNA in urinary bladder cancer: correlation with local relapses. Int J Oncol 1999; 14:1123-1127.
25. Chopin DK, Caruelle JP, Colombel M, et al. Increased immunodetection of acidic fibroblast growth factor in bladder cancer, detectable in urine. J Urol 1993; 150:1126-1130.
26. Joseph A, Weiss GH, Jin L, et al. Expression of scatter factor in human bladder carcinoma. J Natl Cancer Inst 1995; 87:372-377.
27. Ruppert JM, Tokino K, Sidransky D. Evidence for two bladder cancer suppressor loci on human chromosome 9. Cancer Res 1993; 53:5093-5095.
28. Cote RJ, Chatterjee SJ. Molecular determinants of outcome in bladder cancer. Cancer J Sci Am 1999; 5:2-15.
29. Livingstone LR, White A, Sprouse J, et al. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 1992; 70:923-935.
30. el-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75:817-825.
31. Olumi AF, Tsai YC, Nichols PW, et al. Allelic loss of chromosome 17p distinguishes high grade from low grade transitional cell carcinomas of the bladder. Cancer Res 1990; 50:7081-7083.
32. Dalbagni G, Presti JC Jr, Reuter VE, et al. Molecular genetic alterations of chromosome 17 and p53 nuclear overexpression in human bladder cancer. Diagn Mol Pathol 1993; 2:4-13.
33. Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1054 patients. J Clin Oncol 2001; 19:666-675.
34. Shariat SF, Kim J, Raptidis G, et al. Association of p53 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder. Urology 2003; 61:1140-1145.
35. Knudson AG Jr. Retinoblastoma: a prototypic hereditary neoplasm. Semin Oncol 1978; 5:57-60.
36. Chellappan SP, Hiebert S, Mudryj M, et al. The E2F transcription factor is a cellular target for the RB protein. Cell 1991; 65:1053-1061.
37. Sellers WR, Kaelin WG Jr. Role of the retinoblastoma protein in the pathogenesis of human cancer. J Clin Oncol 1997; 15:3301-3312.
38. Schafer KA. The cell cycle: a review. Vet Pathol 1998; 35:461-478.
39. Miyamoto H, Shuin T, Torigoe S, et al. Retinoblastoma gene mutations in primary human bladder cancer. Br J Cancer 1995; 71:831-835.
40. Morgan DO. Principles of CDK regulation. Nature 1995; 374:131-134.
41. Chatterjee SJ, George B, Goebell PJ, et al. Hyperphosphorylation of pRb: a mechanism for RB tumour suppressor pathway inactivation in bladder cancer. J Pathol 2004; 203:762-770.
42. Polyak K, Lee MH, Erdjument-Bromage H, et al. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 1994; 78:59-66.
43. Coats S, Flanagan WM, Nourse J, et al. Requirement of p27Kip1 for restriction point control of the fibroblast cell cycle. Science 1996; 272:877-880.
44. Zhang Y, Xiong Y, Yarbrough WG. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 1998; 92:725-734.
45. Rocco JW, Sidransky D. p16(MTS-1/CDKN2/INK4a) in cancer progression. Exp Cell Res 2001; 264:42-55.
46. Clurman BE, Groudine M. The CDKN2A tumor-suppressor locus--a tale of two proteins. N Engl J Med 1998; 338:910-912.
47. Florl AR, Franke KH, Niederacher D, et al. DNA methylation and the mechanisms of CDKN2A inactivation in transitional cell carcinoma of the urinary bladder. Lab Invest 2000; 80:1513-1522.
48. Berggren P, Kumar R, Sakano S, et al. Detecting homozygous deletions in the CDKN2A(p16(INK4a))/ARF(p14(ARF)) gene in urinary bladder cancer using real-time quantitative PCR. Clin Cancer Res 2003; 9:235-242.
49. Kuo ML, Duncavage EJ, Mathew R, et al. Arf induces p53-dependent and -independent antiproliferative genes. Cancer Res 2003; 63:1046-1053.
50. Wu X, Bayle JH, Olson D, et al. The p53-mdm-2 autoregulatory feedback loop. Genes Dev 1993; 7:1126-1132.
51. Kelly JD, Williamson KE, Irvine AE, et al. Apoptosis and its clinical significance for bladder cancer therapy. BJU Int 1999; 83:1-10.
52. Fesus L, Davies PJ, Piacentini M. Apoptosis: molecular mechanisms in programmed cell death. Eur J Cell Biol 1991; 56:170-177.
53. Chyle V, Pollack A, Czerniak B, et al. Apoptosis and downstaging after preoperative radiotherapy for muscle-invasive bladder cancer. Int J Radiat Oncol Biol Phys 1996; 35:281-287.
54. Lara PC, Perez S, Rey A, et al. Apoptosis in carcinoma of the bladder: relation with radiation treatment results. Int J Radiat Oncol Biol Phys 1999; 43:1015-1019.
55. Moonen L, Ong F, Gallee M, et al. Apoptosis, proliferation and p53, cyclin D1, and retinoblastoma gene expression in relation to radiation response in transitional cell carcinoma of the bladder. Int J Radiat Oncol Biol Phys 2001; 49:1305-1310.
56. Lipponen PK, Aaltomaa S. Apoptosis in bladder cancer as related to standard prognostic factors and prognosis. J Pathol 1994; 173:333-339.
57. Lane DP. Cancer. p53, guardian of the genome. Nature 1992; 358:15-16.
58. Miyashita T, Krajewski S, Krajewska M, et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 1994; 9:1799-1805.
59. Korsmeyer SJ. BCL-2 gene family and the regulation of programmed cell death. Cancer Res 1999; 59:1693s-1700s.
60. Tsujimoto Y, Cossman J, Jaffe E, et al. Involvement of the bcl-2 gene in human follicular lymphoma. Science 1985; 228:1440-1443.
61. Cleary ML, Sklar J. Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18. Proc Natl Acad Sci U S A 1985; 82:7439-7443.
62. Cory S, Huang DC, Adams JM. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 2003; 22:8590-8607.
63. Bernardi P, Broekemeier KM, Pfeiffer DR. Recent progress on regulation of the mitochondrial permeability transition pore; a cyclosporin-sensitive pore in the inner mitochondrial membrane. J Bioenerg Biomembr 1994; 26:509-517.
64. Zoratti M, Szabo I. Electrophysiology of the inner mitochondrial membrane. J Bioenerg Biomembr 1994; 26:543-553.
65. Petit PX, Susin SA, Zamzami N, et al. Mitochondria and programmed cell death: back to the future. FEBS Lett 1996; 396:7-13.
66. Saelens X, Festjens N, Vande Walle L, et al. Toxic proteins released from mitochondria in cell death. Oncogene 2004; 23:2861-2874.
67. Almond JB, Cohen GM. The proteasome: a novel target for cancer chemotherapy. Leukemia 2002; 16:433-443.
68. Ong F, Moonen LM, Gallee MP, et al. Prognostic factors in transitional cell cancer of the bladder: an emerging role for Bcl-2 and p53. Radiother Oncol 2001; 61:169-175.
69. Cooke PW, James ND, Ganesan R, et al. Bcl-2 expression identifies patients with advanced bladder cancer treated by radiotherapy who benefit from neoadjuvant chemotherapy. BJU Int 2000; 85:829-835.
70. Miyake H, Hanada N, Nakamura H, et al. Overexpression of Bcl-2 in bladder cancer cells inhibits apoptosis induced by cisplatin and adenoviral-mediated p53 gene transfer. Oncogene 1998; 16:933-943.
71. Miyake H, Hara I, Yamanaka K, et al. Overexpression of Bcl-2 enhances metastatic potential of human bladder cancer cells. Br J Cancer 1999; 79:1651-1656.
72. Gazzaniga P, Gradilone A, Silvestri I, et al. Variable levels of bcl-2, bcl-x and bax mRNA in bladder cancer progression. Oncol Rep 1998; 5:901-904.
73. Lebedeva I, Raffo A, Rando R, et al. Chemosensitization of bladder carcinoma cells by bcl-xL antisense oligonucleotides. J Urol 2001; 166:461-469.
74. Lee JW, Soung YH, Kim SY, et al. Inactivating mutations of proapoptotic Bad gene in human colon cancers. Carcinogenesis 2004; 25:1371-1376.
75. Scheid MP, Duronio V. Dissociation of cytokine-induced phosphorylation of Bad and activation of PKB/akt: involvement of MEK upstream of Bad phosphorylation. Proc Natl Acad Sci U S A 1998; 95:7439-7444.
76. Kwon CH, Zhu X, Zhang J, et al. Pten regulates neuronal soma size: a mouse model of Lhermitte-Duclos disease. Nat Genet 2001; 29:404-411.
77. Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997; 275:1943-1947.
78. Aveyard JS, Skilleter A, Habuchi T, et al. Somatic mutation of PTEN in bladder carcinoma. Br J Cancer 1999; 80:904-908.
79. Tanaka M, Koul D, Davies MA, et al. MMAC1/PTEN inhibits cell growth and induces chemosensitivity to doxorubicin in human bladder cancer cells. Oncogene 2000; 19:5406-5412.
80. De Giorgi F, Lartigue L, Bauer MK, et al. The permeability transition pore signals apoptosis by directing Bax translocation and multimerization. FASEB J 2002; 16:607-609.
81. Giannopoulou I, Nakopoulou L, Zervas A, et al. Immunohistochemical study of pro-apoptotic factors Bax, Fas and CPP32 in urinary bladder cancer: prognostic implications. Urol Res 2002; 30:342-345.
82. Korkolopoulou P, Lazaris ACh, Konstantinidou AE, et al. Differential expression of bcl-2 family proteins in bladder carcinomas. Relationship with apoptotic rate and survival. Eur Urol 2002; 41:274-283.
83. Ye D, Li H, Qian S, et al. bcl-2/bax expression and p53 gene status in human bladder cancer: relationship to early recurrence with intravesical chemotherapy after resection. J Urol 1998; 160:2025-2028.
84. Jiang X, Wang X. Cytochrome c promotes caspase-9 activation by inducing nucleotide binding to Apaf-1. J Biol Chem 2000; 275:31199-31203.
85. Jia L, Srinivasula SM, Liu FT, et al. Apaf-1 protein deficiency confers resistance to cytochrome c-dependent apoptosis in human leukemic cells. Blood 2001; 98:414-421.
86. Zou H, Li Y, Liu X, et al. An APAF-1-cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9. J Biol Chem 1999; 274:11549-11556.
87. Saleh A, Srinivasula SM, Acharya S, et al. Cytochrome c and dATP-mediated oligomerization of Apaf-1 is a prerequisite for procaspase-9 activation. J Biol Chem 1999; 274:17941-17945.
88. Hajra KM, Liu JR. Apoptosome dysfunction in human cancer. Apoptosis 2004; 9:691-704.
89. Slee EA, Adrain C, Martin SJ. Serial killers: ordering caspase activation events in apoptosis. Cell Death Differ 1999; 6:1067-1074.
90. Burton PB, Anderson CJ, Corbishly CM. Caspase 3 and p27 as predictors of invasive bladder cancer. N Engl J Med 2000; 343:1418-1420.
91. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990; 82:4-6.
92. Weidner N, Semple JP, Welch WR, et al. Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med 1991; 324:1-8.
93. Bochner BH, Cote RJ, Weidner N, et al. Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. J Natl Cancer Inst 1995; 87:1603-1612.
94. Dameron KM, Volpert OV, Tainsky MA, et al. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994; 265:1582-1584.
95. Campbell SC, Volpert OV, Ivanovich M, et al. Molecular mediators of angiogenesis in bladder cancer. Cancer Res 1998; 58:1298-1304.
96. Wenger RH, Gassmann M. Oxygen(es) and the hypoxia-inducible factor-1. Biol Chem 1997; 378:609-616.
97. Huang LE, Gu J, Schau M, et al. Regulation of hypoxia-inducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci U S A 1998; 95:7987-7992.
98. Ryan HE, Lo J, Johnson RS. HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J 1998; 17:3005-3015.
99. Maxwell PH, Dachs GU, Gleadle JM, et al. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci U S A 1997; 94:8104-8109.
100. Forsythe JA, Jiang BH, Iyer NV, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996; 16:4604-4613.
101. Ahmed A, Dunk C, Kniss D, et al. Role of VEGF receptor-1 (Flt-1) in mediating calcium-dependent nitric oxide release and limiting DNA synthesis in human trophoblast cells. Lab Invest 1997; 76:779-791.
102. Klotz T, Bloch W, Jacobs G, et al. Immunolocalization of inducible and constitutive nitric oxide synthases in human bladder cancer. Urology 1999; 54:416-419.
103. Crew JP, O'Brien T, Bradburn M, et al. Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. Cancer Res 1997; 57:5281-5285.
104. Bernardini S, Fauconnet S, Chabannes E, et al. Serum levels of vascular endothelial growth factor as a prognostic factor in bladder cancer. J Urol 2001; 166:1275-1279.
105. Brown NS, Jones A, Fujiyama C, et al. Thymidine phosphorylase induces carcinoma cell oxidative stress and promotes secretion of angiogenic factors. Cancer Res 2000; 60:6298-6302.
106. Jones A, Fujiyama C, Turner K, et al. Role of thymidine phosphorylase in an in vitro model of human bladder cancer invasion. J Urol 2002; 167:1482-1486.
107. O'Brien TS, Fox SB, Dickinson AJ, et al. Expression of the angiogenic factor thymidine phosphorylase/platelet-derived endothelial cell growth factor in primary bladder cancers. Cancer Res 1996; 56:4799-4804.
108. Arima J, Imazono Y, Takebayashi Y, et al. Expression of thymidine phosphorylase as an indicator of poor prognosis for patients with transitional cell carcinoma of the bladder. Cancer 2000; 88:1131-1138.
109. Nutt JE, Mellon JK, Qureshi K, et al. Matrix metalloproteinase-1 is induced by epidermal growth factor in human bladder tumour cell lines and is detectable in urine of patients with bladder tumours. Br J Cancer 1998; 78:215-220.
110. Inoue K, Slaton JW, Kim SJ, et al. Interleukin 8 expression regulates tumorigenicity and metastasis in human bladder cancer. Cancer Res 2000; 60:2290-2299.
111. Elkin M, Ariel I, Miao HQ, et al. Inhibition of bladder carcinoma angiogenesis, stromal support, and tumor growth by halofuginone. Cancer Res 1999; 59:4111-4118.
112. Montesano R, Vassalli JD, Baird A, et al. Basic fibroblast growth factor induces angiogenesis in vitro. Proc Natl Acad Sci U S A 1986; 83:7297-7301.
113. Partridge CR, Hawker JR Jr, Forough R. Overexpression of a secretory form of FGF-1 promotes MMP-1-mediated endothelial cell migration. J Cell Biochem 2000; 78:487-499.
114. Cronauer MV, Schulz WA, Seifert HH, et al. Fibroblast growth factors and their receptors in urological cancers: basic research and clinical implications. Eur Urol 2003; 43:309-319.
115. McCawley LJ, O'Brien P, Hudson LG. Epidermal growth factor (EGF)- and scatter factor/hepatocyte growth factor (SF/HGF)- mediated keratinocyte migration is coincident with induction of matrix metalloproteinase (MMP)-9. J Cell Physiol 1998; 176:255-265.
116. Pepper MS, Ferrara N, Orci L, et al. Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. Biochem Biophys Res Commun 1991; 181:902-906.
117. Wun TC. Plasminogen activation: biochemistry, physiology, and therapeutics. Crit Rev Biotechnol 1988; 8:131-148.
118. Sahni A, Francis CW. Plasmic degradation modulates activity of fibrinogen-bound fibroblast growth factor-2. J Thromb Haemost 2003; 1:1271-1277.
119. Mars WM, Zarnegar R, Michalopoulos GK. Activation of hepatocyte growth factor by the plasminogen activators uPA and tPA. Am J Pathol 1993; 143:949-958.
120. Nguyen M, Watanabe H, Budson AE, et al. Elevated levels of the angiogenic peptide basic fibroblast growth factor in urine of bladder cancer patients. J Natl Cancer Inst 1993; 85:241-242.
121. Chatterjee SJ, Datar R, Youssefzadeh D, et al. Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. J Clin Oncol 2004; 22:1007-1013.
122. Shariat SF, Tokunaga H, Zhou J, et al. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J Clin Oncol 2004; 22:1014-1024.
123. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403:503-511.
124. Yeoh EJ, Ross ME, Shurtleff SA, et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 2002; 1:133-143.
125. van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415:530-536.
126. Aaboe M, Marcussen N, Jensen KM, et al. Gene expression profiling of noninvasive primary urothelial tumours using microarrays. Br J Cancer 2005; 93:1182-1190.
127. Aebersold R, Mann M. Mass spectrometry-based proteomics. Nature 2003; 422:198-207.
128. Shen Y, Smith RD. Proteomics based on high-efficiency capillary separations. Electrophoresis 2002; 23:3106-3124.
129. Lee KH. Proteomics: a technology-driven and technology-limited discovery science. Trends Biotechnol 2001; 19:217-222.
130. Liu W, Guan M, Wu D, et al. Using tree analysis pattern and SELDI-TOF-MS to discriminate transitional cell carcinoma of the bladder cancer from noncancer patients. Eur Urol 2005; 47:456-462.
131. Gorelik E, Landsittel DP, Marrangoni AM, et al. Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer. Cancer Epidemiol Biomarkers Prev 2005; 14:981-987.
132. Mitra AP, Lin H, Cote RJ, et al. Biomarker profiling for cancer diagnosis, prognosis and therapeutic management. Natl Med J India 2005; 18:304-312.
133. Winquist E, Kirchner TS, Segal R, et al. Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. J Urol 2004; 171:561-569.
134. Sylvester R, Sternberg C. The role of adjuvant combination chemotherapy after cystectomy in locally advanced bladder cancer: what we do not know and why. Ann Oncol 2000; 11:851-856.
135. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Adjuvant chemotherapy for invasive bladder cancer (individual patient data). Cochrane Database Syst Rev 2006; (2):CD006018.
136. Cote RJ, Esrig D, Groshen S, et al. p53 and treatment of bladder cancer. Nature 1997; 385:123-125.
137. Waldman T, Lengauer C, Kinzler KW, et al. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature 1996; 381:713-716.
138. Cote RJ, Datar RH. Therapeutic approaches to bladder cancer: identifying targets and mechanisms. Crit Rev Oncol Hematol 2003; 46:S67-S83.
139. Mitra AP, Datar RH, Cote RJ. Molecular staging of bladder cancer. BJU Int 2005; 96:7-12.